Contact Us

Paxil
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Age of patient when antidepressant(s) prescribed:

What condition was this medication prescribed to treat?

What additional medications were you taking at the time?

Did patient hurt themselves during or after taking the drug?

Did patient become violent during or after taking the drug?

Was suicide attempted?

Was hospitalization or institutionalization required after taking antidepressant(s)?

Did loved one commit suicide?

If patient did attempt or commit suicide, did patient ever attempt suicide previously?

If patient did commit suicide, what was the method of suicide?

Please describe violent or suicidal behavior:

If you ever tried to stop taking Paxil and experienced withdrawal, please describe the withdrawal side effects:

Please further describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


BBC: Glaxo Hid Safety Concerns Related to Seroxat (Paxil)

Jan 31, 2007 | NewsInferno.com

According to journalists at the BBC, GlaxoSmithKline intentionally distorted and covered up damaging information about their antidepressant Seroxat and its link to an increased risk of suicide in children. Researchers for the BBC documentary series Panorama obtained three critical documents suggesting that the company had conducted trials proving the drug was unsafe, but failed to accurately disclose that information. (Seroxat is a brand name for paroxetine, a selective serotonin reuptake inhibitor (SSRI) class of antidepressant marketed in the U.S. as Paxil.)

The BBC’s website reports: “GSK’s biggest clinical trial of Seroxat on children was held in the U.S. in the 1990s and called Study 329. Child psychiatrist Dr. Neal Ryan of the University of Pittsburgh was paid by GSK as a co-author of Study 329. In 2002, he also gave a talk on childhood depression at a medical conference sponsored by GSK. He said that Seroxat could be a suitable treatment for children and later told Panorama reporter Shelley Jofre that it probably lowered rather than raised suicide rates.”

The BBC program quotes U.S. attorney Karen Barth Menzies as saying, “They didn’t tell the regulators or the physicians or parents about these risks or the lack of efficacy; instead they went out and promoted this specific study as remarkably effective and safe for kids.”

The BBC’s Jofre later discovered that, after sending questions about the safety of Seroxat to Ryan in 2002, Ryan forwarded them to GSK asking for advice on how to respond. Jofre also found an email from a public-relations executive, saying, “Originally we had planned to do extensive media relations surrounding this study until we actually viewed the results. Essentially the study did not really show it was effective in treating adolescent depression, which is not something we want to publicize.”

The Panorama investigation also found two other incriminating documents, one from GSK’s marketing department in 1999 that acknowledged the safety risks and another from 2001 that reiterated to its sales staff the safety and efficacy of the drug in treating adolescents even after the company was aware of the side effects.

“Even when they have negative studies that show that this drug Seroxat is going to harm some kids, they still spin that study as remarkably effective and safe for children,” added Menzies, a plaintiff attorney in a U.S. suit facing GSK over the drug.

Roughly 50,000 British children took the drug before it was banned in 2003 for use by patients under the age of 18. The documentary claims that GSK knew of the risks in the late 1990s.

In a statement responding to the BBC allegations, Glaxo says: “No suicides were reported in any of the nine pediatric trials conducted by GSK and when reviewed individually none of these trials were considered by GSK or independent investigators to show a clinically meaningful increase in the rate of suicidal thinking or attempted suicide.

“Only when all the data became available, at the end of the research program, and were analyzed together, was an increased rate of suicidal thinking or attempted suicide revealed in those pediatric patients taking Seroxat.”


Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo